Toremifene: The Long Lost Cousin to Nolvadex

Toremifene, known commercially as Fareston, is a triphenylethylene cousin to Nolvadex/Tamoxifen. Clinical literature describes Fareston as having a higher affinity for the estrogen receptor than Nolvadex. This would mean that in theory, Fareston would be a better blocker of estrogen because a higher affinity would allow the drug to more easily displace the naturally circulating estradiol.

Like Nolvadex, Fareston acts as a weak estrogen and binds the estrogen receptor alpha (the receptor subtype which is of most concern to us preventing negative effects of estradiol). Fareston, while acting in studies on post-menopausal women as an anti-estrogen in the breast, acts as an estrogen AGONIST in the uterus. What this means to us is that its estrogenic properties are very similar to Nolvadex in various areas of the body with respect to receptor affinity. Therefore, we can assume the effects of this anti-estrogen drug to be very similar to Nolvadex.

Fareston has a similar half-life to Nolvadex of 5 days, is eliminated primarily in the feces, and has a very high bioavailability. Despite the high bioavailability, this drug needs to be taken for a minimum of one month before steady state is reached in the plasma. Typical pill doses are 60mg and typically 60mg per day is taken for breast cancer patients. This also a sufficient dose for anabolics users to prevent gynecomastia and control estrogenic side effects.